Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• MabeNW, FoxDB, LupoR, et al. Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer. J Clin Invest. 2018;128(10):4413–4428. doi:10.1172/JCI9948130148456
   PubMed Web of Science ®Google Scholar
• AsagaS, KuoC, NguyenT, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91. doi:10.1373/clinchem.2010.15184521036945
   PubMed Web of Science ®Google Scholar
• TaplinS, AbrahamL, BarlowWE, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Nat Cancer Inst. 2008;100(12):876–887. doi:10.1093/jnci/djn17218544742
   PubMedGoogle Scholar
• HarrisL, FritscheH, MennelR, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–5312. doi:10.1200/JCO.2007.14.236417954709
   PubMed Web of Science ®Google Scholar
• UeharaM, KinoshitaT, HojoT, et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 2008;13(5):447. doi:10.1007/s10147-008-0773-318946756
   PubMed Web of Science ®Google Scholar
• DuffyMJ, EvoyD, McDermottEW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010;411(23–24):1869–1874. doi:10.1016/j.cca.2010.08.03920816948
   PubMed Web of Science ®Google Scholar
• LinS, GregoryRI. MicroRNA biogenesis pathways in cancer. Nature Rev Cancer. 2015;15(6):321. doi:10.1038/nrc393225998712
   PubMed Web of Science ®Google Scholar
• WangN, WangL, YangY, GongL, XiaoB, LiuX. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Biochem Biophys Res Commun. 2017;493(3):1322–1328. doi:10.1016/j.bbrc.2017.10.00328986250
   PubMed Web of Science ®Google Scholar
• ZhouX, WenW, ZhuJ, et al. A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma. Oncotarget. 2017;8(21):34468.28380431
   PubMedGoogle Scholar
• van SchooneveldE, WildiersH, VergoteI, VermeulenPB, DirixLY, Van LaereSJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015;17(1):21. doi:10.1186/s13058-015-0526-y25849621
   PubMed Web of Science ®Google Scholar
• XueJ, NiuJ, WuJ, WuZ-H. MicroRNAs in cancer therapeutic response: friend and foe. World J Clin Oncol. 2014;5(4):730–743. doi:10.5306/wjco.v5.i4.73025302173
   PubMedGoogle Scholar
• YanL-X, LiuY-H, XiangJ-W, et al. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer. Int J Oncol. 2016;48(2):471–484. doi:10.3892/ijo.2015.328726676464
   PubMed Web of Science ®Google Scholar
• LiJ, ZhangY, ZhangW, et al. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Surg Oncol. 2013;2013(1):1–7. doi:10.1155/2013/875078
   Google Scholar
• PanX, WangR, WangZX. The potential role of miR-451 in cancer diagnosis, prognosis, and therapy. Mol Cancer Ther. 2013;12(7):1153–1162. doi:10.1158/1535-7163.MCT-12-080223814177
   PubMed Web of Science ®Google Scholar
• SuZ, ZhaoJ, RongZ, et al. MiR-451, a potential prognostic biomarker and tumor suppressor for gastric cancer. Int J Clin Exp Pathol. 2015;8(8):9154.26464660
   PubMed Web of Science ®Google Scholar
• KonishiH, IchikawaD, KomatsuS, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Brit J Cancer. 2012;106(4):740–747. doi:10.1038/bjc.2011.58822262318
   PubMed Web of Science ®Google Scholar
• PfafflMW. Quantification strategies in real-time PCR: the real-time PCR encyclopedia A–Z of quantitative PCR. Inte Univer Line La Jolla. 2004;1(1):89–113.
   Google Scholar
• BahramiA, AledavoodA, AnvariK, et al. The prognostic and therapeutic application of microRNAs in breast cancer: tissue and circulating microRNAs. J Cell Physiol. 2018;233(2):774–786. doi:10.1002/jcp.2581328109133
   PubMed Web of Science ®Google Scholar
• HamamR, HamamD, AlsalehKA, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017;8(9):3045. doi:10.1038/cddis.2017.518
   PubMed Web of Science ®Google Scholar
• GlingeC, ClaussS, BoddumK, et al. Stability of circulating blood-based microRNAs–pre-analytic methodological considerations. PLoS One. 2017;12(2):0167969. doi:10.1371/journal.pone.0167969
   PubMed Web of Science ®Google Scholar
• SiH, SunX, ChenY, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2013;139(2):223–229. doi:10.1007/s00432-012-1315-y23052693
   PubMed Web of Science ®Google Scholar
• LiB-S, ZhaoY-L, GuoG, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7(7):41629. doi:10.1371/journal.pone.0041629
   PubMed Web of Science ®Google Scholar
• ZhangH, MaoF, ShenT, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncology Lett. 2017;13(2):669–676. doi:10.3892/ol.2016.5462
   PubMed Web of Science ®Google Scholar
• TsukamotoM, IinumaH, YagiT, MatsudaK, HashiguchiY. Circulating exosomal microRNA-21 as a biomarker in each tumor stage of colorectal cancer. Oncology. 2017;92(6):360–370. doi:10.1159/00046338728376502
   PubMed Web of Science ®Google Scholar
• HanJ-G, JiangY-D, ZhangC-H, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res. 2017;92(2):55–66. doi:10.4174/astr.2017.92.2.5528203552
   PubMed Web of Science ®Google Scholar
• YanL-X, HuangX-F, ShaoQ, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348–2360. doi:10.1261/rna.103480818812439
   PubMed Web of Science ®Google Scholar
• WangG, WangL, SunS, WuJ, WangQ. Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. Ann Lab Med. 2015;35(2):226–232. doi:10.3343/alm.2015.35.2.22625729725
   PubMed Web of Science ®Google Scholar
• KumarswamyR, VolkmannI, ThumT. Regulation and function of of miR-21 in health and disease. RNA Biol. 2011;8(5):706–713. doi:10.4161/rna.8.5.1615421712654
   PubMed Web of Science ®Google Scholar
• WangZ-X, Lu-B-B, WangH, ChengZ-X, YinY-M. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res. 2011;42(4):281–290. doi:10.1016/j.arcmed.2011.06.00821820606
   PubMed Web of Science ®Google Scholar
• GongC, YaoY, WangY, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 2011;286(21):19127–19137. doi:10.1074/jbc.M110.21688721471222
   PubMed Web of Science ®Google Scholar
• XieZ, CaoL, ZhangJ. miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1α expression in human ovarian cancer cells. Oncol Lett. 2013;6(3):795–800. doi:10.3892/ol.2013.143224137413
   PubMed Web of Science ®Google Scholar
• WangG, YaoL, YangT, et al. MiR-451 suppresses the growth, migration, and invasion of prostate cancer cells by targeting macrophage migration inhibitory factor. Transl Cancer Res. 2019;8(1):647–654. doi:10.21037/tcr.2019.03.28
   Web of Science ®Google Scholar
• MamooriA, WahabR, ViderJ, et al. The tumour suppressor effects and regulation of cancer stem cells by macrophage migration inhibitory factor targeted miR-451 in colon cancer. Gene. 2019;697(2):165–174. doi:10.1016/j.gene.2019.02.04630802541
   PubMed Web of Science ®Google Scholar
• ChanM, LiawCS, JiSM, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 2013;19(16):4477–4487. doi:10.1158/1078-0432.CCR-12-340123797906
   PubMed Web of Science ®Google Scholar
• CukK, ZucknickM, HeilJ, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132(7):1602–1612. doi:10.1002/ijc.2779922927033
   PubMed Web of Science ®Google Scholar
• WangZ, ZhangH, ZhangP, et al. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol. 2013;30(2):577. doi:10.1007/s12032-013-0577-923609190
   PubMed Web of Science ®Google Scholar
• ZhuH, WuH, LiuX, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76(5):582–588. doi:10.1016/j.bcp.2008.06.00718619946
   PubMed Web of Science ®Google Scholar
• KovalchukO, FilkowskiJ, MeservyJ, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7(7):2152–2159. doi:10.1158/1535-7163.MCT-08-002118645025
   PubMed Web of Science ®Google Scholar
• MotamediM, Hashemzadeh ChaleshtoriM, GhasemiS, et al. The association of mir-451 and mir-21 in plasma with lymph node metastases in breast cancer. J Babol Univ Med Sci. 2018;20(4):12–16.
   Google Scholar